Dr. Yu Tian, Jiangsu University, China
Dr. Yu Tian is a prominent researcher at Jiangsu University, China, specializing in immunology and molecular biology. With a focus on immune cell migration, viral myocarditis, and neuroinflammation, Dr. Tian has contributed significantly to understanding immune responses in cardiovascular and neurological diseases. He has published numerous articles in prestigious journals such as Journal of Leukocyte Biology and International Immunopharmacology, and his research explores therapeutic targets like HMGB1 and IL-22. Dr. Tian’s work plays a critical role in advancing treatment strategies for diseases involving immune system dysfunction and inflammation.
Dr. Yu Tian completed his Bachelor’s Degree in Medicine at Qinghai University from September 2011 to June 2016. He then pursued his Master’s and Ph.D. at Jiangsu University, School of Medicine, from September 2016 to September 2022, where he specialized in immunology and molecular biology. His academic journey has laid a strong foundation for his research in immune cell function and disease mechanisms, contributing to his current role as a researcher at Jiangsu University.
Dr. Yu Tian is currently a researcher at Jiangsu University, School of Life Sciences, specifically within the International Genomics Research Center, a position he has held since December 2022. In this role, he leads a horizontal research project investigating the effects of HMGB1 on immune cells, which commenced in 2023. Additionally, Dr. Tian is actively involved in a National Natural Science Foundation of China (NSFC)-funded project that examines the role of IGF-1 in heart damage following myocardial infarction, scheduled for 2025 to 2027. His work contributes significantly to advancing the understanding of immune mechanisms in cardiovascular health.
Research Interest:
Dr. Yu Tian’s research interests lie in immunology, specifically investigating the role of HMGB1 in immune cell responses. He focuses on cardiovascular diseases, exploring the mechanisms that contribute to heart damage and myocardial infarction. Additionally, Dr. Tian studies adipose tissue accumulation and its impact on worsening heart conditions, aiming to uncover potential therapeutic targets for improving cardiovascular health. His work seeks to enhance the understanding of immune and metabolic interactions in the context of heart disease.
Dr. Yu Tian is an accomplished researcher at Jiangsu University, specializing in immunology and cardiovascular diseases. With a solid educational background and a focus on the role of HMGB1 in immune responses, he is dedicated to unraveling the complex mechanisms underlying heart damage and myocardial infarction. His ongoing research projects aim to deepen the understanding of immune cell interactions and metabolic factors that exacerbate cardiovascular conditions. Through his contributions, Dr. Tian is poised to make a significant impact on the field, advancing potential therapeutic strategies for improving heart health and addressing related diseases.
Yin, P., Su, Z., Shu, X., Dong, Z., Tian, Y. (2024). Role of TREM2 in immune and neurological diseases: Structure, function, and implications. International Immunopharmacology, 143, 113286. 0 citations
Tian, Y., Gong, X., Qin, D., Liu, F., Su, Z. (2023). S1PR1-dependent migration of ILC3s from intestinal tissue to the heart in a mouse model of viral myocarditis. Journal of Leukocyte Biology, 114(2), 154–163. 7 citations
Tian, Y., Chen, R., Su, Z. (2023). HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson’s Disease. Cellular and Molecular Neurobiology, 43(1), 47–58. 6 citations
Chen, R., Liu, F., Xia, L., Xu, H., Su, Z. (2022). B10 cells decrease fibrosis progression following cardiac injury partially by IL-10 production and regulating hyaluronan secretion. Journal of Leukocyte Biology, 111(2), 415–425. 1 citation
Cao, Y., Tian, Y., Liu, Y., Su, Z. (2022). Reg3β: A Potential Therapeutic Target for Tissue Injury and Inflammation-Associated Disorders. International Reviews of Immunology, 41(2), 160–170. 2 citations
Che, Y., Tian, Y., Chen, R., Liu, F., Su, Z. (2021). IL-22 ameliorated cardiomyocyte apoptosis in cardiac ischemia/reperfusion injury by blocking mitochondrial membrane potential decrease, inhibiting ROS and cytochrome C. Biochimica et Biophysica Acta – Molecular Basis of Disease, 1867(9), 166171. 26 citations
Chen, W., Yao, S., Wan, J., Yao, Y., Zhang, X. (2021). BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment. Journal of Controlled Release, 333, 129–138. 45 citations
Li, J., Xia, L., Liu, F., Chen, R., Su, Z. (2021). lncRNA187415.1 silence in BCAMs ameliorated breast cancer progression by blocking C/EBPβ-lncRNA187415.1-CISH axis and reversing pro-tumor characteristic of BCAMs. Clinical and Translational Medicine, 11(5), e407. 1 citation
Huang, L., Wan, J., Wu, Y., Su, Z., Xu, H. (2021). Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Life Sciences, 270, 119142. 26 citations
Wan, J., Wu, Y., Huang, L., Wang, S., Xu, H. (2021). ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8+ T cells. Cancer Letters, 502, 34–43. 31 citations
